Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
EP3368007B1	THERAPEUTIC USE OF A STERILE AQUEOUS OPHTHALMIC SOLUTION	The present invention relates to a sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 µmol/g polymer to 280 µmol/g polymer, for use in the treatment of corneal wounds.	1. A sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 µmol/g polymer to 280 µmol/g polymer, for use in the treatment of corneal wounds.	Croma-Pharma Gesellschaft m.b.H., 2100 Leobendorf, AT, 101049731 | CROMA PHARMA GES M B H	2020-03-18	2015-10-30
EP3159011B1	OPHTHALMIC COMPOSITION	The present invention relates to an ophthalmic composition which is an aqueous composition having pH between 7 and 7.4, osmolarity between 280 and 300 mOsm/1, and which comprises one or more glycosaminoglycans (GAGs), wherein said composition has a contact angle measured over a Kapton surface in the range of about 50° and 80°. In a further aspect, said composition is claimed for use in the epithelial protection in femto-assisted eye surgery.	1. An ophthalmic composition which is an aqueous composition having pH between 7 and 7.4, osmolarity between 280 and 300 mOsm/l, and which comprises one or more glycosaminoglycans (GAGs) in amounts ranging between 0.1 and 5% w/w, polyvinyl alcohol (PVA) in a concentration between 0.1 and 0.5% w/w, glycerol in amounts ranging between 0.5 and 1% w/w, sodium chloride between 0.01 and 1% w/w, disodium phosphate between 0.1 and 1% w/w, wherein said composition has a contact angle measured over a Kapton surface in the range of 50° to 80°, wherein said contact angle is measured as a static contact angle by means of the sessile drop method with the instrument Contact Angle System OCAE15, wherein the drop has a volume of 3 µl and the deposition rate is 1 µl/s, wherein the measurement time after the drop deposition is 50 seconds.	Medivis S.R.L., 95127 Catania (CT), IT, 101286266 | MEDIVIS S R L	2020-03-18	2015-10-20
EP3199160B1	AQUEOUS COMPOSITION	An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition comprising a compound represented by Formula (1), wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a quaternary ammonium surfactant.	1. An aqueous composition comprising ripasudil, or a salt thereof, or a solvate of the compound or the salt thereof, and benzalkonium chloride, wherein the content of the benzalkonium chloride in the aqueous composition is 0.0001 to 0.01 w/v% based on the total volume of the aqueous composition. 3. A method for providing an aqueous composition with an antiseptic effect, comprising the step of incorporating ripasudil or a salt thereof, or a solvate of the compound or the salt thereof, and benzalkonium chloride, wherein the content of the benzalkonium chloride in the aqueous composition is 0.0001 to 0.01 w/v% based on the total volume of the aqueous composition.	Kowa Company Ltd., Nagoya-shi, Aichi-ken 460-8625, JP, 100781512 | KOWA CO	2020-03-11	2014-09-25
EP3102246B1	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION	Compositions and methods for treating macular degeneration are disclosed. The methods utilize gene delivery to human eyes of soluble Flt-1 receptors, as well fusion proteins including a soluble Flt-1 receptor.	1. A recombinant adeno-associated virus (rAAV) virion comprising a polynucleotide encoding a soluble protein comprising at least one domain of VEGFR-1 (Flt-1) capable of inhibiting VEGF activity for use in the treatment of wet age-related macular degeneration or macular edema in a human subject by delivering from 1 x 10 8 up to 2 x 10 9 rAAV virions to the diseased eye of the subject.	Genzyme Corporation, Cambridge, MA 02142, US, 101748345 | GENZYME CORP	2020-03-25	2014-02-06
EP2928475B1	FINAFLOXACIN SUSPENSION COMPOSITIONS	The present invention relates to methods for treating an ophthalmic, otic, or nasal infection	1. A topical suspension composition comprising finafloxacin, a solubilizer, and a suspending agent,	Merlion Pharmaceuticals Pte. Ltd., Singapore 088702, SG,	2020-03-04	2012-12-06

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		comprising treating the infected tissue with a suspension composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin free base or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.	wherein the concentration of said finafloxacin or a pharmaceutically acceptable salt thereof is 0.15 to 2.0 w/v%, said solubilizer is magnesium salt at a concentration of 0.98 to 4.9 mM and said suspending agent is hydroxyethylcellulose at a concentration of 0.1 to 0.3 w/v% and wherein said composition has a pH of 5.8 to 6.2.	101777617 | MERLION PHARMACEUTICALS PTE LTD		
EP2922919B1	COMPOSITIONS AND METHODS FOR REDUCING OXIDATIVE DAMAGE	Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.	1. A polymeric composition, comprising a poly(ethylene glycol), a viscoelastic polymer, that is hyaluronic acid, an initiator for promoting polymerisation of the poly(ethylene glycol) and the viscoelastic polymer, and an antioxidant which is trehalose, wherein, in polymerized form, the composition has a refractive index, measured according to the method disclosed in the experimental part of this specification, of 1.30 to 1.40, wherein the initiator is a photo initiator which is a combination of eosin Y, triethanolamine and N-vinyl-2-pyrrolidinone and wherein the poly(ethylene glycol) is poly(ethylene glycol) diacrylate.	University Of Louisville Research Foundation Inc., Louisville, KY 40202, US, 101091679 | UNIV LOUISVILLE RES FOUND INC	2020-03-25	2012-11-21
EP2909232B1	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)	The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.	1. A Rod-derived Cone Viability Factor Long isoform (RdCVFL) polynucleotide or polypeptide for use in a method for the treatment of age-related macular degeneration (AMD) in a subject in need thereof, by reducing the malondialdehyde (MDA) level in the retina.	Institut National de la Santé et de la Recherche Médicale (INSERM), 75013 Paris, FR, 101330597 | Centre National de la Recherche Scientifique (C.N.R.S.), 75016 Paris, FR, 101336357 | INST NAT SANTE RECH MED | CENTRE NAT RECH SCIENT	2020-03-11	2012-10-17
EP2846847B1	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.	1. An in vivo gelling ophthalmic pre-formulation comprising: (a) at least one first compound comprising more than one nucleophilic group, wherein the first compound is pentaerythritol polyethylene glycol amine (4ARM-PEG-NH2), hexaglycerol polyethylene glycol amine (8ARM-PEG-NH2), pentaerythritol polyethylene glycol amino acetate (4ARM-PEG-AA) or hexaglycerol polyethylene glycol amino acetate (8ARM-PEG-AA); (b) at least one second compound comprising more than one electrophilic group, wherein the second compound is pentaerythritol polyethylene glycol succinimidyl glutaramide (4ARM-PEG-SGA) or hexaglycerol polyethylene glycol succinimidyl glutarate (8ARM-PEG-SG); (c) an aqueous buffer in the pH range of 6.0 to 8.5; and (d) a viscosity enhancer; wherein the in vivo gelling ophthalmic formulation at least in part	C.P. Medical Corporation, Norcross, Georgia 30093, US, 101851850 | C P MEDICAL CORP	2020-03-25	2012-05-11

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			polymerizes and/or gels at a target site of an eye to form a biocompatible retinal patch.			
EP2827837B1	EXOPOLYSACCHARIDE FOR THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR NAILS	Exopolysaccharide of a bacterial strain for its use in treatment and/or care of the skin, mucous membranes, hair and/or nails, as well as its cosmetic and/or dermopharmaceutical compositions. In particular, for the aging of skin and in particular for the treatment and/or prevention of wrinkles.	1. Use of exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277 to improve the hydration of the skin, mucous membranes, hair and/or nails, wherein said use is cosmetic and non-therapeutic. 2. A non-therapeutic method of treatment and/or care of the skin, mucous membranes, hair and/or nails which comprises the administration of a cosmetically effective quantity of the exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277, wherein said treatment and/or care is the treatment and/or prevention of aging. 4. A method of treatment and/or care of the skin, mucous membranes, hair and/or nails which comprises the administration of a cosmetically effective quantity of the exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277, wherein said treatment and/or care is treatment stimulating hair growth and/or prevention of hair loss. 5. Exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277 for use in the treatment and/or care of the skin, mucous membranes, hair and/or nails, wherein said treatment and/or care is of xerosis, corns and calluses, atopic dermatitis, acne, ichthyosis, chapped lips, vaginal dryness and/or ocular dryness. 6. Exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277 for use in the treatment and/or care of the skin, mucous membranes, hair and/or nails, wherein said treatment and/or care is a reepithelization and/or healing treatment of the skin and/or mucous membranes. 7. Exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277 for use in the treatment and/or care of the skin, mucous membranes, hair and/or nails, wherein said treatment and/or care is the treatment and/or prevention of pain or itching of the skin, mucous membranes and/or nails. 9. Exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277 for its use in the treatment and/or care of the skin, mucous membranes, hair and/or nails, wherein said treatment and/or care is the treatment and/or prevention of hyperhidrosis of the skin, mucous membranes and/or nails. 10. Use of exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277 for	Lubrizol Advanced Materials Inc., Cleveland, OH 44141-3247, US, 100972116 | Polymaris Biotechnology, 29600 Morlaix, FR, 101319247 | LUBRIZOL ADVANCED MAT INC | POLYMARIS BIOTECHNOLOGY	2020-03-11	2012-03-22

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			the non-therapeutic treatment and/or care of dry skin and/or dry hair. 15. Cosmetic or dermopharmaceutical composition comprising an effective cosmetic or dermopharmaceutical quantity of the exopolysaccharide of the strain of the species Vibrio sp. with deposit number CNCM I-4277, and at least one cosmetically or dermopharmaceutically acceptable excipient, adjuvant and/or ingredient.			
EP2787968B1	EFFICIENT LIPID DELIVERY TO HUMAN TEAR FILM USING A SALT-SENSITIVE EMULSION SYSTEM	Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.	1. A low salt ophthalmic pharmaceutical composition comprising a sub-micron emulsion, a polymer lubricant, and a salt-sensitive viscosity modulating polymer, wherein said sub-micron emulsion comprises a surfactant and a therapeutic lipid; wherein said therapeutic lipid is castor oil; wherein said surfactant is a sorbitan ester; wherein said salt-sensitive viscosity modulating polymer is an acrylate/C 10 -C 30 acrylate crosspolymer; wherein said polymer lubricant is carboxymethylcellulose sodium; and wherein said castor oil is present at a concentration of about 0.25% (w/w), wherein about refers to the nominal amount ± 10% thereof, wherein low salt refers to a salt content which is sufficiently low so as to provide a stabilized sub-micron emulsion within the ophthalmic pharmaceutical composition.	ALLERGAN INC., Irvine, CA 92612, US, 100074706 | ALLERGAN INC	2020-03-04	2011-12-07
EP2485691B1	OPHTHALMIC DRUG DELIVERY		1. A medicament for use in the treatment of a disease or a condition of the eye of a subject, wherein said medicament is provided as a plurality of ejected droplets generated by an ejector device having an ejector plate coupled to a piezoelectric actuator, wherein the droplets have an average droplet size that is in the range of about 20 microns to about 100 microns in diameter; and the droplets have an average droplet ejecting velocity of between 0.5 m/s and 20 m/s; and wherein between about 80% to about 100% of the ejected mass of said droplets is deposited on the eye, wherein the medicament is selected from the group consisting of ranibizumab antibody FAB (including Lucentis), VEGF Trap fusion molecule (including VEGF Trap-Eye), microplasmin enzyme (including Ocriplasmin), macugen pegylated polypeptide (including Pegaptanib), bevacizumab (including Avastin), carboxymethylcellulose sodium, tetrahydrozoline HCl, pheniramine maleate, ketotifen fumarate, oxymetazoline HCl, naphazoline HCl, moxifloxacin hydrochloride, bromfenac, proparacaine hydrochloride, difluprednate, gatifloxacin, travoprost, bepotastine besilate, gatifloxacin, loteprednol etabonate, timolol ophthalmic, olopatadine hydrochloride, phenylephrine hydrochloride, levofloxacin, ketorolac tromethamine,	Eyenovia Inc., New York, NY 10017, US, 101854824 | EYENOVIA INC	2020-03-18	2010-07-15

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			letanoprost, bimatoprost, BAK free latanoprost, fluorosilicone acrylate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, propylene glycol, hypromellose, zinc sulfate, dorzolamide, HCl timolol maleate, azithromycin, nepafenac, brinzolamide, besifloxacin, prenisone acetate, tobramycin, gentamycin, tobramycin/dexamethasone, cyclosporine, timolol maleate, and brimonidine tartrate.			